Connect with us

Business

Brazil researchers now say China’s Sinovac vaccine is 50% effective — lower than announced earlier – CNBC

The Butantan Institute had said last week that CoronaVac was 78% effective among volunteers with mild to severe infections, reported the Wall Street Journal.

Published

on

post featured image
ADVERTISEMENT

Covid-19 vaccines developed by China’s Sinovac Biotech are displayed during a press conference in Beijing on Sept. 24, 2020.
The Covid-19 vaccine developed by China’s Sinovac Biotechis just 50.4% effective in a Brazilian trial barely meeting the threshold for regulatory approval and well below the initially reported efficacy rate, according to several media reports.  
Brazil is the first to complete late-stage trial of the vaccine CoronaVac. The state-run Butantan Institute has been criticized by…

Click here to view the original article.

Continue Reading
Advertisement

You might also like ...

Oil-Rich Abu Dhabi Targets Hydrogen as Future Export Fuel – Bloomberg
post featured image
Jamie Lynn Spears Implicates Elon Musk in the Death of Her Cats – Vulture
post featured image
Top Tech Stocks for 2021 – Motley Fool